Loading...
Header Logo
Keywords
Last Name
Institution

DIHUA YU

TitleProfessor
InstitutionMD Anderson
DepartmentMolecular & Cellular Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Yuzhalin AE, Yu D. Brain Metastasis Organotropism. Cold Spring Harb Perspect Med. 2019 Sep 23. PMID: 31548224.
      View in: PubMed
    2. Acharya S, Yao J, Li P, Zhang C, Lowery FJ, Zhang Q, Guo H, Qu J, Yang F, Wistuba II, Piwnica-Worms H, Sahin AA, Yu D. Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer. Cancer Res. 2019 Aug 15; 79(16):4211-4226. PMID: 31239273.
      View in: PubMed
    3. Hu Q, Ye Y, Chan LC, Li Y, Liang K, Lin A, Egranov SD, Zhang Y, Xia W, Gong J, Pan Y, Chatterjee SS, Yao J, Evans KW, Nguyen TK, Park PK, Liu J, Coarfa C, Donepudi SR, Putluri V, Putluri N, Sreekumar A, Ambati CR, Hawke DH, Marks JR, Gunaratne PH, Caudle AS, Sahin AA, Hortobagyi GN, Meric-Bernstam F, Chen L, Yu D, Hung MC, Curran MA, Han L, Lin C, Yang L. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol. 2019 07; 20(7):835-851. PMID: 31160797.
      View in: PubMed
    4. Zhang L, Yu D. Exosomes in cancer development, metastasis, and immunity. Biochim Biophys Acta Rev Cancer. 2019 04; 1871(2):455-468. PMID: 31047959.
      View in: PubMed
    5. Yu D. Working together to make AJCR stronger. Am J Cancer Res. 2018; 8(1):1. PMID: 29416915.
      View in: PubMed
    6. Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, Yao J, Mangala LS, Li C, Yang W, Park PK, Hawke DH, Zhou J, Zhou Y, Xia W, Hung MC, Marks JR, Gallick GE, Lopez-Berestein G, Flores ER, Sood AK, Huang S, Yu D, Yang L, Lin C. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest. 2017 12 01; 127(12):4498-4515. PMID: 29130936.
      View in: PubMed
    7. Yang J, Joshi S, Wang Q, Li P, Wang H, Xiong Y, Xiao Y, Wang J, Parker-Thornburg J, Behringer RR, Yu D. 14-3-3? loss leads to neonatal lethality by microRNA-126 downregulation-mediated developmental defects in lung vasculature. Cell Biosci. 2017; 7:58. PMID: 29118970.
      View in: PubMed
    8. Wang X, Yao J, Wang J, Zhang Q, Brady SW, Arun B, Seewaldt VL, Yu D. Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention. Cancer Prev Res (Phila). 2017 Nov; 10(11):641-650. PMID: 28877935.
      View in: PubMed
    9. Gall VA, Philips AV, Qiao N, Clise-Dwyer K, Perakis AA, Zhang M, Clifton GT, Sukhumalchandra P, Ma Q, Reddy SM, Yu D, Molldrem JJ, Peoples GE, Alatrash G, Mittendorf EA. Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. Cancer Res. 2017 10 01; 77(19):5374-5383. PMID: 28819024.
      View in: PubMed
    10. Joshi S, Yang J, Wang Q, Li P, Wang H, Zhang Q, Xiong Y, Pickering BF, Parker-Thornburg J, Behringer RR, Yu D. 14-3-3? loss impedes oncogene-induced mammary tumorigenesis and metastasis by attenuating oncogenic signaling. Am J Cancer Res. 2017; 7(8):1654-1664. PMID: 28861322.
      View in: PubMed
    11. Zhang C, Lowery FJ, Yu D. Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis. J Vis Exp. 2017 02 08; (120). PMID: 28287553.
      View in: PubMed
    12. Zhang C, Yu D. Advances in decoding breast cancer brain metastasis. Cancer Metastasis Rev. 2016 12; 35(4):677-684. PMID: 27873078.
      View in: PubMed
    13. Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, Chang SS, Lin WC, Hsu JM, Hsu YH, Kim T, Chang WC, Hsu JL, Yamaguchi H, Ding Q, Wang Y, Yang Y, Chen CH, Sahin AA, Yu D, Hortobagyi GN, Hung MC. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. 2016 Dec 12; 30(6):925-939. PMID: 27866850.
      View in: PubMed
    14. Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Ding Q, Wang Y, Yao J, Lee CC, Wu HJ, Sahin AA, Allison JP, Yu D, Hortobagyi GN, Hung MC. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016 08 30; 7:12632. PMID: 27572267.
      View in: PubMed
    15. Chang CC, Zhang C, Zhang Q, Sahin O, Wang H, Xu J, Xiao Y, Zhang J, Rehman SK, Li P, Hung MC, Behbod F, Yu D. Upregulation of lactate dehydrogenase a by 14-3-3? leads to increased glycolysis critical for breast cancer initiation and progression. Oncotarget. 2016 Jun 07; 7(23):35270-83. PMID: 27150057.
      View in: PubMed
    16. Bowie M, Pilie P, Wulfkuhle J, Lem S, Hoffman A, Desai S, Petricoin E, Carter A, Ambrose A, Seewaldt V, Yu D, Ibarra Drendall C. Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer. World J Clin Oncol. 2015 Dec 10; 6(6):299-311. PMID: 26677444.
      View in: PubMed
    17. Rahal OM, Nie L, Chan LC, Li CW, Hsu YH, Hsu J, Yu D, Hung MC. Selective expression of constitutively active pro-apoptotic protein BikDD gene in primary mammary tumors inhibits tumor growth and reduces tumor initiating cells. Am J Cancer Res. 2015; 5(12):3624-34. PMID: 26885451.
      View in: PubMed
    18. Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang WC, Li P, Li M, Wang X, Zhang C, Wang H, Ellis K, Cheerathodi M, McCarty JH, Palmieri D, Saunus J, Lakhani S, Huang S, Sahin AA, Aldape KD, Steeg PS, Yu D. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. 2015 Nov 05; 527(7576):100-104. PMID: 26479035.
      View in: PubMed
    19. Jain S, Wang X, Chang CC, Ibarra-Drendall C, Wang H, Zhang Q, Brady SW, Li P, Zhao H, Dobbs J, Kyrish M, Tkaczyk TS, Ambrose A, Sistrunk C, Arun BK, Richards-Kortum R, Jia W, Seewaldt VL, Yu D. Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer. Cancer Res. 2015 Nov 15; 75(22):4863-75. PMID: 26383165.
      View in: PubMed
    20. Kanojia D, Balyasnikova IV, Morshed RA, Frank RT, Yu D, Zhang L, Spencer DA, Kim JW, Han Y, Yu D, Ahmed AU, Aboody KS, Lesniak MS. Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases. Stem Cells. 2015 Oct; 33(10):2985-94. PMID: 26260958.
      View in: PubMed
    21. Momeny M, Saunus JM, Marturana F, McCart Reed AE, Black D, Sala G, Iacobelli S, Holland JD, Yu D, Da Silva L, Simpson PT, Khanna KK, Chenevix-Trench G, Lakhani SR. Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. Oncotarget. 2015 Feb 28; 6(6):3932-46. PMID: 25668816.
      View in: PubMed
    22. Xu J, Acharya S, Sahin O, Zhang Q, Saito Y, Yao J, Wang H, Li P, Zhang L, Lowery FJ, Kuo WL, Xiao Y, Ensor J, Sahin AA, Zhang XH, Hung MC, Zhang JD, Yu D. 14-3-3? turns TGF-ß's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. Cancer Cell. 2015 Feb 09; 27(2):177-92. PMID: 25670079.
      View in: PubMed
    23. Brady SW, Zhang J, Tsai MH, Yu D. PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition. Cancer Biol Ther. 2015; 16(3):402-11. PMID: 25692408.
      View in: PubMed
    24. Boulbes DR, Arold ST, Chauhan GB, Blachno KV, Deng N, Chang WC, Jin Q, Huang TH, Hsu JM, Brady SW, Bartholomeusz C, Ladbury JE, Stone S, Yu D, Hung MC, Esteva FJ. HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Mol Oncol. 2015 Mar; 9(3):586-600. PMID: 25435280.
      View in: PubMed
    25. Thirumurthi U, Shen J, Xia W, LaBaff AM, Wei Y, Li CW, Chang WC, Chen CH, Lin HK, Yu D, Hung MC. MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer. Sci Signal. 2014 Jul 29; 7(336):ra71. PMID: 25074979.
      View in: PubMed
    26. Khotskaya YB, Goverdhan A, Shen J, Ponz-Sarvise M, Chang SS, Hsu MC, Wei Y, Xia W, Yu D, Hung MC. S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer. Am J Transl Res. 2014; 6(4):361-76. PMID: 25075253.
      View in: PubMed
    27. Chang Z, Ju H, Ling J, Zhuang Z, Li Z, Wang H, Fleming JB, Freeman JW, Yu D, Huang P, Chiao PJ. Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis. PLoS One. 2014; 9(7):e101452. PMID: 25029561.
      View in: PubMed
    28. Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Wang MY, Li CW, Shen J, Chen MK, Sahin AA, Sood A, Mills GB, Yu D, Hortobagyi GN, Hung MC. Definition of PKC-a, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Res. 2014 Sep 01; 74(17):4822-35. PMID: 24970481.
      View in: PubMed
    29. Sahin O, Wang Q, Brady SW, Ellis K, Wang H, Chang CC, Zhang Q, Priya P, Zhu R, Wong ST, Landis MD, Muller WJ, Esteva FJ, Chang J, Yu D. Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. Cell Res. 2014 May; 24(5):542-59. PMID: 24675532.
      View in: PubMed
    30. Brady SW, Zhang J, Seok D, Wang H, Yu D. Enhanced PI3K p110a signaling confers acquired lapatinib resistance that can be effectively reversed by a p110a-selective PI3K inhibitor. Mol Cancer Ther. 2014 Jan; 13(1):60-70. PMID: 24249715.
      View in: PubMed
    31. Rehman SK, Li SH, Wyszomierski SL, Wang Q, Li P, Sahin O, Xiao Y, Zhang S, Xiong Y, Yang J, Wang H, Guo H, Zhang JD, Medina D, Muller WJ, Yu D. 14-3-3? orchestrates mammary tumor onset and progression via miR-221-mediated cell proliferation. Cancer Res. 2014 Jan 01; 74(1):363-373. PMID: 24197133.
      View in: PubMed
    32. Saldana SM, Lee HH, Lowery FJ, Khotskaya YB, Xia W, Zhang C, Chang SS, Chou CK, Steeg PS, Yu D, Hung MC. Inhibition of type I insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis. PLoS One. 2013; 8(9):e73406. PMID: 24039934.
      View in: PubMed
    33. Kyrish M, Dobbs J, Jain S, Wang X, Yu D, Richards-Kortum R, Tkaczyk TS. Needle-based fluorescence endomicroscopy via structured illumination with a plastic, achromatic objective. J Biomed Opt. 2013 Sep; 18(9):096003. PMID: 24002190.
      View in: PubMed
    34. Zhang S, Huang WC, Zhang L, Zhang C, Lowery FJ, Ding Z, Guo H, Wang H, Huang S, Sahin AA, Aldape KD, Steeg PS, Yu D. SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases. Cancer Res. 2013 Sep 15; 73(18):5764-74. PMID: 23913825.
      View in: PubMed
    35. Ke S, Wang W, Qiu X, Zhang F, Yustein JT, Cameron AG, Zhang S, Yu D, Zou C, Gao X, Lin J, Yallampalli S, Li M. Multiple target-specific molecular agents for detection and image analysis of breast cancer characteristics in mice. Curr Mol Med. 2013 Mar; 13(3):446-58. PMID: 23331017.
      View in: PubMed
    36. Lowery FJ, Yu D. Growth factor signaling in metastasis: current understanding and future opportunities. Cancer Metastasis Rev. 2012 Dec; 31(3-4):479-91. PMID: 22706845.
      View in: PubMed
    37. Wang Q, Li SH, Wang H, Xiao Y, Sahin O, Brady SW, Li P, Ge H, Jaffee EM, Muller WJ, Hortobagyi GN, Yu D. Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Res. 2012 Sep 01; 72(17):4417-28. PMID: 22773664.
      View in: PubMed
    38. Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, Huang HY, Tsai KK, Flores LG, Shao Y, Hazle JD, Yu D, Wei W, Sarbassov D, Hung MC, Nakayama KI, Lin HK. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell. 2012 May 25; 149(5):1098-111. PMID: 22632973.
      View in: PubMed
    39. Kumar A, Xu J, Sung B, Kumar S, Yu D, Aggarwal BB, Mehta K. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells. Breast Cancer Res. 2012 Jan 06; 14(1):R4. PMID: 22225906.
      View in: PubMed
    40. Zhang S, Yu D. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci. 2012 Mar; 33(3):122-8. PMID: 22153719.
      View in: PubMed
    41. Pickering BF, Yu D, Van Dyke MW. Nucleolin protein interacts with microprocessor complex to affect biogenesis of microRNAs 15a and 16. J Biol Chem. 2011 Dec 23; 286(51):44095-103. PMID: 22049078.
      View in: PubMed
    42. Lang JY, Hsu JL, Meric-Bernstam F, Chang CJ, Wang Q, Bao Y, Yamaguchi H, Xie X, Woodward WA, Yu D, Hortobagyi GN, Hung MC. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell. 2011 Sep 13; 20(3):341-56. PMID: 21907925.
      View in: PubMed
    43. Neal CL, Xu J, Li P, Mori S, Yang J, Neal NN, Zhou X, Wyszomierski SL, Yu D. Overexpression of 14-3-3? in cancer cells activates PI3K via binding the p85 regulatory subunit. Oncogene. 2012 Feb 16; 31(7):897-906. PMID: 21743495.
      View in: PubMed
    44. Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nuñez R, Hortobagyi GN, Yu D, Esteva FJ. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol. 2011 Aug 10; 29(23):3126-32. PMID: 21730275.
      View in: PubMed
    45. Kumar A, Gao H, Xu J, Reuben J, Yu D, Mehta K. Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells. PLoS One. 2011; 6(6):e20701. PMID: 21687668.
      View in: PubMed
    46. Ibarra-Drendall C, Troch MM, Barry WT, Broadwater G, Petricoin EF, Wulfkuhle J, Liotta LA, Lem S, Baker JC, Ford AC, Wilke LG, Zalles C, Kuderer NM, Hoffman AW, Shivraj M, Mehta P, Williams J, Tolbert N, Lee LW, Pilie PG, Yu D, Seewaldt VL. Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. Breast Cancer Res Treat. 2012 Apr; 132(2):487-98. PMID: 21647677.
      View in: PubMed
    47. Baker EL, Srivastava J, Yu D, Bonnecaze RT, Zaman MH. Cancer cell migration: integrated roles of matrix mechanics and transforming potential. PLoS One. 2011; 6(5):e20355. PMID: 21647371.
      View in: PubMed
    48. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, Sahin AA, Esteva FJ, Hortobagyi GN, Yu D. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med. 2011 Apr; 17(4):461-9. PMID: 21399647.
      View in: PubMed
    49. Jiffar T, Yilmaz T, Lee J, Hanna E, El-Naggar A, Yu D, Myers JN, Kupferman ME. KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma. Oncogene. 2011 Jul 14; 30(28):3163-73. PMID: 21383688.
      View in: PubMed
    50. Zhang C, Yu D. Microenvironment determinants of brain metastasis. Cell Biosci. 2011 Feb 25; 1(1):8. PMID: 21711688.
      View in: PubMed
    51. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, Yu WH, Rehman SK, Hsu JL, Lee HH, Liu M, Chen CT, Yu D, Hung MC. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol. 2011 Mar; 13(3):317-23. PMID: 21336307.
      View in: PubMed
    52. Pilie PG, Ibarra-Drendall C, Troch MM, Broadwater G, Barry WT, Petricoin EF, Wulfkuhle JD, Liotta LA, Lem S, Baker JC, Stouder A, Ford AC, Wilke LG, Zalles CM, Mehta P, Williams J, Shivraj M, Su Z, Geradts J, Yu D, Seewaldt VL. Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data. Cancer Epidemiol Biomarkers Prev. 2011 Mar; 20(3):476-82. PMID: 21242333.
      View in: PubMed
    53. Pierce M, Yu D, Richards-Kortum R. High-resolution fiber-optic microendoscopy for in situ cellular imaging. J Vis Exp. 2011 Jan 11; (47). PMID: 21248707.
      View in: PubMed
    54. Neal CL, Yu D. 14-3-3? as a prognostic marker and therapeutic target for cancer. Expert Opin Ther Targets. 2010 Dec; 14(12):1343-54. PMID: 21058923.
      View in: PubMed
    55. Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, Horton LW, Zaja-Milatovic S, Collins-Burow BM, Wadsworth S, Beckman BS, Wood CE, Fuqua SA, Nephew KP, Dent P, Worthylake RA, Curiel TJ, Hung MC, Richmond A, Burow ME. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res. 2011 Jan 15; 71(2):603-13. PMID: 21123450.
      View in: PubMed
    56. Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochem Biophys Res Commun. 2010 Dec 03; 403(1):103-7. PMID: 21040707.
      View in: PubMed
    57. Kumar A, Xu J, Brady S, Gao H, Yu D, Reuben J, Mehta K. Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One. 2010 Oct 12; 5(10):e13390. PMID: 20967228.
      View in: PubMed
    58. Baker EL, Lu J, Yu D, Bonnecaze RT, Zaman MH. Cancer cell stiffness: integrated roles of three-dimensional matrix stiffness and transforming potential. Biophys J. 2010 Oct 06; 99(7):2048-57. PMID: 20923638.
      View in: PubMed
    59. Cheng X, Xia W, Yang JY, Hsu JL, Lang JY, Chou CK, Du Y, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis. Cancer Res. 2010 Oct 01; 70(19):7684-9. PMID: 20841468.
      View in: PubMed
    60. Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol. 2010 Oct; 177(4):1647-56. PMID: 20813970.
      View in: PubMed
    61. Zhang S, Yu D. PI(3)king apart PTEN's role in cancer. Clin Cancer Res. 2010 Sep 01; 16(17):4325-30. PMID: 20622047.
      View in: PubMed
    62. Lu J, Yu D. Invasive breast cancer development: "fatal accident" from malfunctions in both "motor" and "brake". Cell Cycle. 2010 Feb 01; 9(3):421-2. PMID: 20090417.
      View in: PubMed
    63. Kupferman ME, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, Xie T, Feng L, Wang J, Holsinger FC, Yu D, Myers JN. TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene. 2010 Apr 08; 29(14):2047-59. PMID: 20101235.
      View in: PubMed
    64. Esteva FJ, Yu D, Hung MC, Hortobagyi GN. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol. 2010 Feb; 7(2):98-107. PMID: 20027191.
      View in: PubMed
    65. Li SH, Hawthorne VS, Neal CL, Sanghera S, Xu J, Yang J, Guo H, Steeg PS, Yu D. Upregulation of neutrophil gelatinase-associated lipocalin by ErbB2 through nuclear factor-kappaB activation. Cancer Res. 2009 Dec 15; 69(24):9163-8. PMID: 19951994.
      View in: PubMed
    66. Lu J, Guo H, Treekitkarnmongkol W, Li P, Zhang J, Shi B, Ling C, Zhou X, Chen T, Chiao PJ, Feng X, Seewaldt VL, Muller WJ, Sahin A, Hung MC, Yu D. 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell. 2009 Sep 08; 16(3):195-207. PMID: 19732720.
      View in: PubMed
    67. Zhao YH, Zhou M, Liu H, Ding Y, Khong HT, Yu D, Fodstad O, Tan M. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene. 2009 Oct 22; 28(42):3689-701. PMID: 19668225.
      View in: PubMed
    68. Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, Cristofanilli M, Dontu G, Bidaut L, Valero V, Hortobagyi GN, Yu D. Breast cancer metastasis: challenges and opportunities. Cancer Res. 2009 Jun 15; 69(12):4951-3. PMID: 19470768.
      View in: PubMed
    69. Liao Y, Wei Y, Zhou X, Yang JY, Dai C, Chen YJ, Agarwal NK, Sarbassov D, Shi D, Yu D, Hung MC. Peptidyl-prolyl cis/trans isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation phosphorylation. Oncogene. 2009 Jul 02; 28(26):2436-45. PMID: 19448664.
      View in: PubMed
    70. Kligys K, Yao J, Yu D, Jones JC. 14-3-3zeta/tau heterodimers regulate Slingshot activity in migrating keratinocytes. Biochem Biophys Res Commun. 2009 Jun 12; 383(4):450-4. PMID: 19371722.
      View in: PubMed
    71. Hawthorne VS, Huang WC, Neal CL, Tseng LM, Hung MC, Yu D. ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells. Mol Cancer Res. 2009 Apr; 7(4):592-600. PMID: 19372587.
      View in: PubMed
    72. Neal CL, Yao J, Yang W, Zhou X, Nguyen NT, Lu J, Danes CG, Guo H, Lan KH, Ensor J, Hittelman W, Hung MC, Yu D. 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res. 2009 Apr 15; 69(8):3425-32. PMID: 19318578.
      View in: PubMed
    73. Hung MC, Mills GB, Yu D. Oxygen sensor boosts growth factor signaling. Nat Med. 2009 Mar; 15(3):246-7. PMID: 19265822.
      View in: PubMed
    74. Lu J, Tan M, Huang WC, Li P, Guo H, Tseng LM, Su XH, Yang WT, Treekitkarnmongkol W, Andreeff M, Symmans F, Yu D. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin Cancer Res. 2009 Feb 15; 15(4):1326-34. PMID: 19228734.
      View in: PubMed
    75. Torti FM, Altieri D, Broach J, Fan H, Lotze M, Manfredi J, Matrisian L, Yu D, Giaccia A. Ph.D. Training in cancer biology. Cancer Res. 2008 Nov 15; 68(22):9122-4. PMID: 19010881.
      View in: PubMed
    76. Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, Albarracin C, Yu D, Abbruzzese JL, Mills GB, Bast RC, Hortobagyi GN, Hung MC. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog. 2008 Sep; 47(9):701-6. PMID: 18176935.
      View in: PubMed
    77. Danes CG, Wyszomierski SL, Lu J, Neal CL, Yang W, Yu D. 14-3-3 zeta down-regulates p53 in mammary epithelial cells and confers luminal filling. Cancer Res. 2008 Mar 15; 68(6):1760-7. PMID: 18339856.
      View in: PubMed
    78. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, Huang H, Kuo HP, Lee DF, Li LY, Lien HC, Cheng X, Chang KJ, Hsiao CD, Tsai FJ, Tsai CH, Sahin AA, Muller WJ, Mills GB, Yu D, Hortobagyi GN, Hung MC. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008 Feb; 10(2):138-48. PMID: 18204439.
      View in: PubMed
    79. Lu CH, Wyszomierski SL, Tseng LM, Sun MH, Lan KH, Neal CL, Mills GB, Hortobagyi GN, Esteva FJ, Yu D. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res. 2007 Oct 01; 13(19):5883-8. PMID: 17908983.
      View in: PubMed
    80. Das P, Kotilingam D, Korchin B, Liu J, Yu D, Lazar AJ, Pollock RE, Lev D. High prevalence of p53 exon 4 mutations in soft tissue sarcoma. Cancer. 2007 Jun 01; 109(11):2323-33. PMID: 17429838.
      View in: PubMed
    81. Hannay JA, Liu J, Zhu QS, Bolshakov SV, Li L, Pisters PW, Lazar AJ, Yu D, Pollock RE, Lev D. Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. Mol Cancer Ther. 2007 May; 6(5):1650-60. PMID: 17513613.
      View in: PubMed
    82. Hannay J, Davis JJ, Yu D, Liu J, Fang B, Pollock RE, Lev D. Isolated limb perfusion: a novel delivery system for wild-type p53 and fiber-modified oncolytic adenoviruses to extremity sarcoma. Gene Ther. 2007 Apr; 14(8):671-81. PMID: 17287860.
      View in: PubMed
    83. Tan M, Yu D. Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Adv Exp Med Biol. 2007; 608:119-29. PMID: 17993237.
      View in: PubMed
    84. Liao Y, Yu D, Hung MC. Novel approaches for chemosensitization of breast cancer cells: the E1A story. Adv Exp Med Biol. 2007; 608:144-69. PMID: 17993239.
      View in: PubMed
    85. Lu J, Yu D. Adenoviral-Vector Based siRNA for Mutant K-ras as a Promising Tool for Lung Cancer Gene Therapy: A License to Kill. Cancer Biol Ther. 2006 Dec; 5(12):1724-5. PMID: 17224631.
      View in: PubMed
    86. De Clerck YA, Weissman BE, Yu D, Parsons R, Bar-Eli M, Roy-Burman P, Seewaldt VL, Cress AE, Languino LR, Batra SK, Tang CK, Sheng S, Chen WT, Chellappan S, Cheng SY, Ladisch S, McCarthy JB, Coussens LM, Cohen MB. Tumor progression and metastasis from genetic to microenvironmental determinants: a workshop of the tumor progression and metastasis NIH study section in honor of Dr. Martin L. Padarathsingh, May 31, 2006, Georgetown, Washington, DC. Cancer Biol Ther. 2006 Dec; 5(12):1588-99. PMID: 17224636.
      View in: PubMed
    87. Akkiprik M, Nicorici D, Cogdell D, Jia YJ, Hategan A, Tabus I, Yli-Harja O, Y D, Sahin A, Zhang W. Dissection of signaling pathways in fourteen breast cancer cell lines using reverse-phase protein lysate microarray. Technol Cancer Res Treat. 2006 Dec; 5(6):543-51. PMID: 17121430.
      View in: PubMed
    88. Ping B, He X, Xia W, Lee DF, Wei Y, Yu D, Mills G, Shi D, Hung MC. Cytoplasmic expression of p21CIP1/WAF1 is correlated with IKKbeta overexpression in human breast cancers. Int J Oncol. 2006 Nov; 29(5):1103-10. PMID: 17016640.
      View in: PubMed
    89. Liu J, Zhan M, Hannay JA, Das P, Bolshakov SV, Kotilingam D, Yu D, Lazar AF, Pollock RE, Lev D. Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis. Mol Cancer Res. 2006 Nov; 4(11):803-10. PMID: 17077165.
      View in: PubMed
    90. Zhang L, Hannay JA, Liu J, Das P, Zhan M, Nguyen T, Hicklin DJ, Yu D, Pollock RE, Lev D. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. Cancer Res. 2006 Sep 01; 66(17):8770-8. PMID: 16951193.
      View in: PubMed
    91. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006 May; 3(5):269-80. PMID: 16683005.
      View in: PubMed
    92. Tan M, Lan KH, Yao J, Lu CH, Sun M, Neal CL, Lu J, Yu D. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res. 2006 Apr 01; 66(7):3764-72. PMID: 16585203.
      View in: PubMed
    93. Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, Yang W, Yin G, Hittelman WN, Yu D. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res. 2006 Feb 15; 66(4):2028-37. PMID: 16489002.
      View in: PubMed
    94. Konopleva M, Zhang W, Shi YX, McQueen T, Tsao T, Abdelrahim M, Munsell MF, Johansen M, Yu D, Madden T, Safe SH, Hung MC, Andreeff M. Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. Mol Cancer Ther. 2006 Feb; 5(2):317-28. PMID: 16505105.
      View in: PubMed
    95. Tan M, Li P, Sun M, Yin G, Yu D. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene. 2006 Jun 01; 25(23):3286-95. PMID: 16407820.
      View in: PubMed
    96. Efferson CL, Tsuda N, Kawano K, Nistal-Villán E, Sellappan S, Yu D, Murray JL, García-Sastre A, Ioannides CG. Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells. J Virol. 2006 Jan; 80(1):383-94. PMID: 16352563.
      View in: PubMed
    97. Wyszomierski SL, Yu D. A knotty turnabout?: Akt1 as a metastasis suppressor. Cancer Cell. 2005 Dec; 8(6):437-9. PMID: 16338656.
      View in: PubMed
    98. Lan KH, Lu CH, Yu D. Mechanisms of trastuzumab resistance and their clinical implications. Ann N Y Acad Sci. 2005 Nov; 1059:70-5. PMID: 16382045.
      View in: PubMed
    99. Tan M, Li P, Klos KS, Lu J, Lan KH, Nagata Y, Fang D, Jing T, Yu D. ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Res. 2005 Mar 01; 65(5):1858-67. PMID: 15753384.
      View in: PubMed
    100. Thomas DG, Giordano TJ, Sanders D, Biermann S, Sondak VK, Trent JC, Yu D, Pollock RE, Baker L. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer. 2005 Feb 15; 103(4):830-8. PMID: 15641030.
      View in: PubMed
    101. Henson JD, Hannay JA, McCarthy SW, Royds JA, Yeager TR, Robinson RA, Wharton SB, Jellinek DA, Arbuckle SM, Yoo J, Robinson BG, Learoyd DL, Stalley PD, Bonar SF, Yu D, Pollock RE, Reddel RR. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res. 2005 Jan 01; 11(1):217-25. PMID: 15671549.
      View in: PubMed
    102. Zhan M, Yu D, Liu J, Glazer RI, Hannay J, Pollock RE. Transcriptional repression of protein kinase Calpha via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation. J Biol Chem. 2005 Feb 11; 280(6):4825-33. PMID: 15563462.
      View in: PubMed
    103. Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, Hung MC. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell. 2004 Nov; 6(5):459-69. PMID: 15542430.
      View in: PubMed
    104. Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res. 2004 Oct 15; 10(20):6779-88. PMID: 15501954.
      View in: PubMed
    105. Hawthorne VS, Yu D. PI3K: Missense Mutation Motivates Malignancy. Cancer Biol Ther. 2004 Aug; 3(8):776-7. PMID: 15280668.
      View in: PubMed
    106. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004 Aug; 6(2):117-27. PMID: 15324695.
      View in: PubMed
    107. Sellappan S, Grijalva R, Zhou X, Yang W, Eli MB, Mills GB, Yu D. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res. 2004 May 15; 64(10):3479-85. PMID: 15150101.
      View in: PubMed
    108. Klos KS, Yu D. Liposomal mediated transfer of ErbB2 antisense DNA: coming of age in the war against cancer. Cancer Biol Ther. 2004 Feb; 3(2):205-6. PMID: 14764991.
      View in: PubMed
    109. Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y, Yu D. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer. 2003 Oct 01; 98(7):1377-85. PMID: 14508823.
      View in: PubMed
    110. Yang W, Klos KS, Zhou X, Yao J, Yang Y, Smith TL, Shi D, Yu D. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression. Cancer. 2003 Sep 15; 98(6):1123-30. PMID: 12973835.
      View in: PubMed
    111. Hannay JA, Yu D. Silibinin: a thorny therapeutic for EGF-R expressing tumors? Cancer Biol Ther. 2003 Sep-Oct; 2(5):532-3. PMID: 14614321.
      View in: PubMed
    112. Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res. 2002 Oct 15; 62(20):5703-10. PMID: 12384528.
      View in: PubMed
    113. Hu M, Nicolson GL, Trent JC, Yu D, Zhang L, Lang A, Killary A, Ellis LM, Bucana CD, Pollock RE. Characterization of 11 human sarcoma cell strains: evaluation of cytogenetics, tumorigenicity, metastasis, and production of angiogenic factors. Cancer. 2002 Oct 01; 95(7):1569-76. PMID: 12237927.
      View in: PubMed
    114. Yang W, Klos K, Yang Y, Smith TL, Shi D, Yu D. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer. 2002 Jun 01; 94(11):2855-61. PMID: 12115372.
      View in: PubMed
    115. Tan M, Jing T, Lan KH, Neal CL, Li P, Lee S, Fang D, Nagata Y, Liu J, Arlinghaus R, Hung MC, Yu D. Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol Cell. 2002 May; 9(5):993-1004. PMID: 12049736.
      View in: PubMed
    116. Zhang L, Yu D, Hicklin DJ, Hannay JA, Ellis LM, Pollock RE. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Res. 2002 Apr 01; 62(7):2034-42. PMID: 11929822.
      View in: PubMed
    117. Brandt B, Roetger A, Bidart JM, Packeisen J, Schier K, Mikesch JH, Kemming D, Boecker W, Yu D, Buerger H. Early placenta insulin-like growth factor (pro-EPIL) is overexpressed and secreted by c-erbB-2-positive cells with high invasion potential. Cancer Res. 2002 Feb 15; 62(4):1020-4. PMID: 11861376.
      View in: PubMed
    118. Oksvold M, Huitfeldt H, Stang E, Madshus I. Localizing the EGF receptor. Nat Cell Biol. 2002 Feb; 4(2):E22; author reply E22-3. PMID: 11835048.
      View in: PubMed
    119. Yao J, Xiong S, Klos K, Nguyen N, Grijalva R, Li P, Yu D. Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene. 2001 Dec 06; 20(56):8066-74. PMID: 11781819.
      View in: PubMed
    120. Yu D. Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers. Semin Oncol. 2001 Oct; 28(5 Suppl 16):12-7. PMID: 11706391.
      View in: PubMed
    121. Zhan M, Yu D, Lang A, Li L, Pollock RE. Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression. Cancer. 2001 Sep 15; 92(6):1556-66. PMID: 11745235.
      View in: PubMed
    122. Makino K, Yu D, Hung MC. Transcriptional upregulation and activation of p55Cdc via p34(cdc2) in Taxol-induced apoptosis. Oncogene. 2001 May 03; 20(20):2537-43. PMID: 11420663.
      View in: PubMed
    123. Xiong S, Grijalva R, Zhang L, Nguyen NT, Pisters PW, Pollock RE, Yu D. Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-beta1-activated p38 signaling pathway enhances endothelial cell migration. Cancer Res. 2001 Feb 15; 61(4):1727-32. PMID: 11245489.
      View in: PubMed
    124. Ueno NT, Yu D, Hung MC. E1A: tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy. Breast Cancer. 2001; 8(4):285-93. PMID: 11791119.
      View in: PubMed
    125. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. 2000 Dec 11; 19(53):6115-21. PMID: 11156524.
      View in: PubMed
    126. Grothey A, Hashizume R, Ji H, Tubb BE, Patrick CW, Yu D, Mooney EE, McCrea PD. C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene. 2000 Oct 05; 19(42):4864-75. PMID: 11039904.
      View in: PubMed
    127. Yu D, Hung MC. Role of erbB2 in breast cancer chemosensitivity. Bioessays. 2000 Jul; 22(7):673-80. PMID: 10878580.
      View in: PubMed
    128. Zhang L, Yu D, Hu M, Xiong S, Lang A, Ellis LM, Pollock RE. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res. 2000 Jul 01; 60(13):3655-61. PMID: 10910082.
      View in: PubMed
    129. Milas M, Yu D, Lang A, Ge T, Feig B, El-Naggar AK, Pollock RE. Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity. Cancer Gene Ther. 2000 Mar; 7(3):422-9. PMID: 10766348.
      View in: PubMed
    130. Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, Price J, Paul RW, Anklesaria P, Yu D, Hung MC. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res. 2000 Jan; 6(1):250-9. PMID: 10656456.
      View in: PubMed
    131. Feig BW, Lu X, Hunt KK, Shan Q, Yu D, Pollock R, Chiao P. Inhibition of the transcription factor nuclear factor-kappa B by adenoviral-mediated expression of I kappa B alpha M results in tumor cell death. Surgery. 1999 Aug; 126(2):399-405. PMID: 10455913.
      View in: PubMed
    132. Tan M, Grijalva R, Yu D. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase. Cancer Res. 1999 Apr 01; 59(7):1620-5. PMID: 10197638.
      View in: PubMed
    133. Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ, Hung MC. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell. 1998 Nov; 2(5):581-91. PMID: 9844631.
      View in: PubMed
    134. Milas M, Yu D, Pollock RE. Advances in the understanding of human soft tissue sarcomas: molecular biology and therapeutic strategies (Review). Oncol Rep. 1998 Sep-Oct; 5(5):1275-9. PMID: 9683850.
      View in: PubMed
    135. Yu D. The role of oncogenes in drug resistance. Cytotechnology. 1998 Sep; 27(1-3):283-92. PMID: 19002799.
      View in: PubMed
    136. Pollock R, Lang A, Ge T, Sun D, Tan M, Yu D. Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control. Clin Cancer Res. 1998 Aug; 4(8):1985-94. PMID: 9717829.
      View in: PubMed
    137. Yu D, Hung MC. The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A. Cancer Metastasis Rev. 1998 Jun; 17(2):195-202. PMID: 9770116.
      View in: PubMed
    138. Milas M, Yu D, Sun D, Pollock RE. Telomerase activity of sarcoma cell lines and fibroblasts is independent of p53 status. Clin Cancer Res. 1998 Jun; 4(6):1573-9. PMID: 9626480.
      View in: PubMed
    139. Yu D, Liu B, Jing T, Sun D, Price JE, Singletary SE, Ibrahim N, Hortobagyi GN, Hung MC. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene. 1998 Apr 23; 16(16):2087-94. PMID: 9572489.
      View in: PubMed
    140. Yao J, Pollock RE, Lang A, Tan M, Pisters PW, Goodrich D, El-Naggar A, Yu D. Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma. Clin Cancer Res. 1998 Apr; 4(4):1065-70. PMID: 9563903.
      View in: PubMed
    141. Milas M, Feig B, Yu D, Oriuchi N, Cromeens D, Ge T, Wong FC, Kim EE, Pollock R. Isolated limb perfusion in the sarcoma-bearing rat: a novel preclinical gene delivery system. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2197-203. PMID: 9815615.
      View in: PubMed
    142. Brader KR, Wolf JK, Hung MC, Yu D, Crispens MA, van Golen KL, Price JE. Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism. Clin Cancer Res. 1997 Nov; 3(11):2017-24. PMID: 9815592.
      View in: PubMed
    143. Liu B, Sun D, Xia W, Hung MC, Yu D. Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1) J Natl Cancer Inst. 1997 Oct 15; 89(20):1524-9. PMID: 9337349.
      View in: PubMed
    144. Ueno NT, Yu D, Hung MC. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene. 1997 Aug 18; 15(8):953-60. PMID: 9285690.
      View in: PubMed
    145. Chen H, Yu D, Chinnadurai G, Karunagaran D, Hung MC. Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu. Oncogene. 1997 Apr 24; 14(16):1965-71. PMID: 9150363.
      View in: PubMed
    146. Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 1997 Mar 15; 57(6):1199-205. PMID: 9067293.
      View in: PubMed
    147. Singletary SE, Dhingra K, Yu DH. New strategies in locally advanced breast cancer. Cancer Treat Res. 1997; 90:253-71. PMID: 9367088.
      View in: PubMed
    148. Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene. 1996 Sep 19; 13(6):1359-65. PMID: 8808711.
      View in: PubMed
    149. Pollock RE, Lang A, Luo J, El-Naggar AK, Yu D. Soft tissue sarcoma metastasis from clonal expansion of p53 mutated tumor cells. Oncogene. 1996 May 02; 12(9):2035-9. PMID: 8649865.
      View in: PubMed
    150. Yu D, Matin A, Xia W, Sorgi F, Huang L, Hung MC. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene. 1995 Oct 05; 11(7):1383-8. PMID: 7478560.
      View in: PubMed
    151. Gum R, Wang SW, Lengyel E, Yu D, Hung MC, Juarez J, Boyd D. Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene. Anticancer Res. 1995 Jul-Aug; 15(4):1167-72. PMID: 7653995.
      View in: PubMed
    152. Hung MC, Matin A, Zhang Y, Xing X, Sorgi F, Huang L, Yu D. HER-2/neu-targeting gene therapy--a review. Gene. 1995 Jun 14; 159(1):65-71. PMID: 7607574.
      View in: PubMed
    153. Zhang Y, Yu D, Xia W, Hung MC. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogene. 1995 May 18; 10(10):1947-54. PMID: 7761095.
      View in: PubMed
    154. Tsai CM, Yu D, Chang KT, Wu LH, Perng RP, Ibrahim NK, Hung MC. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. J Natl Cancer Inst. 1995 May 03; 87(9):682-4. PMID: 7538595.
      View in: PubMed
    155. Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL, Hung MC. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res. 1994 Jun 15; 54(12):3260-6. PMID: 7911396.
      View in: PubMed
    156. Yu D, Matin A, Hinds PW, Hung MC. Transcriptional regulation of neu by RB and E1A in rat-1 cells. Cell Growth Differ. 1994 Apr; 5(4):431-8. PMID: 8043517.
      View in: PubMed
    157. Yu D, Shi D, Scanlon M, Hung MC. Reexpression of neu-encoded oncoprotein counteracts the tumor-suppressing but not the metastasis-suppressing function of E1A. Cancer Res. 1993 Dec 01; 53(23):5784-90. PMID: 7902209.
      View in: PubMed
    158. Yu D, Wolf JK, Scanlon M, Price JE, Hung MC. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 1993 Feb 15; 53(4):891-8. PMID: 8094034.
      View in: PubMed
    159. Yu D, Hamada J, Zhang H, Nicolson GL, Hung MC. Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. Oncogene. 1992 Nov; 7(11):2263-70. PMID: 1359495.
      View in: PubMed
    160. Yu D, Matin A, Hung MC. The retinoblastoma gene product suppresses neu oncogene-induced transformation via transcriptional repression of neu. J Biol Chem. 1992 May 25; 267(15):10203-6. PMID: 1350277.
      View in: PubMed
    161. Chan JC, Scanlon M, Zhang HZ, Jia LB, Yu DH, Hung MC, French M, Eastman EM. Molecular cloning and characterization of v-mos-activated transformation-associated proteins. J Biol Chem. 1992 Jan 15; 267(2):1099-103. PMID: 1370458.
      View in: PubMed
    162. Shi D, He G, Cao S, Pan W, Zhang HZ, Yu D, Hung MC. Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Mol Carcinog. 1992; 5(3):213-8. PMID: 1350198.
      View in: PubMed
    163. Yu DH, Hung MC. Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene. 1991 Nov; 6(11):1991-6. PMID: 1682865.
      View in: PubMed
    164. Yu DH, Scorsone K, Hung MC. Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene. Mol Cell Biol. 1991 Mar; 11(3):1745-50. PMID: 1671710.
      View in: PubMed
    165. Yu D, Suen TC, Yan DH, Chang LS, Hung MC. Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci U S A. 1990 Jun; 87(12):4499-503. PMID: 1972274.
      View in: PubMed
    166. Selective expression of constitutively active pro-apoptotic protein BikDD gene in primary mammary tumors inhibits tumor growth and reduces tumor initiating cells. American Journal of Cancer Research. 5:3624-3634.
    167. Erratum. Journal of Biological Chemistry. 280:22555.
    168. Erratum. Nature Cell Biology. 13:1466.
    169. Downregulation of GLUT4 contributes to effective intervention of estrogen receptor-negative/HER2-overexpressing early stage breast disease progression by lapatinib. American Journal of Cancer Research. 6:981-995.
    170. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. Breast Diseases. 16:53-54.
    171. HER2-positive breast cancers make more CXCR4 which helps them invade and metastasize. Cancer Biology and Therapy. 3:1195-1196.
    172. Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. Oncotarget. 6:3932-3946.
    173. Upregulation of lactate dehydrogenase a by 14-3-3ζ leads to increased glycolysis critical for breast cancer initiation and progression. Oncotarget. 7:35270-35283.
    174. Advances in decoding breast cancer brain metastasis. Cancer and Metastasis Reviews. 35:677-684.
    175. Erratum. Nature Cell Biology. 13:1467.
    176. S6k1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer. American Journal of Translational Research. 6:361-376.
    177. Src inhibition blocks c-Myc translation and glucose metabolism to prevent the development of breast cancer. Cancer Research. 75:4863-4875.
    178. High-resolution fiber-optic microendoscopy for in situ cellular imaging. Journal of Visualized Experiments.
    179. Erratum. Cell. 151:913-914.
    180. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nature Communications. 7.
    181. Targeting the EGFR family of receptor tyrosine kinases. 843-853.
    182. Advances in Experimental Medicine and Biology. Advances in Experimental Medicine and Biology. 608.
    183. Erratum. Breast Cancer Research and Treatment. 135:925.
    184. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. 30:925-939.
    185. PTEN key to Herceptin response in Her2-positive breast cancer. Cancer Biology and Therapy. 3:796.
    186. Mechanisms of breast cancer resistance to chemotherapy. 783-803.
    187. Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer. World Journal of Clinical Oncology. 6:299-311.
    188. Brain metastasis. Biochimica et Biophysica Acta - Reviews on Cancer. 1867:49-57.
    189. Microtubule-associated protein tau. Breast Diseases. 16:374-375.
    190. Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases. Stem Cells. 33:2985-2994.
    YU's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description